Publishing research using ab63097? Please let us know so that we can cite the reference in this datasheet.

ab63097 has been referenced in 8 publications.

  • Wu J  et al. Wnt-ß-catenin signaling pathway inhibition by sclerostin may protect against degradation in healthy but not osteoarthritic cartilage. Mol Med Rep 15:2423-2432 (2017). IHC-P ; Human . PubMed: 28259981
  • Xu Y  et al. Sclerostin is essential for alveolar bone loss in occlusal hypofunction. Exp Ther Med 11:1812-1818 (2016). PubMed: 27168809
  • Wu L  et al. Sclerostin expression in the subchondral bone of patients with knee osteoarthritis. Int J Mol Med 38:1395-1402 (2016). WB, IHC-P ; Human . PubMed: 27665782
  • Thompson WR  et al. Osteocyte specific responses to soluble and mechanical stimuli in a stem cell derived culture model. Sci Rep 5:11049 (2015). PubMed: 26056071
  • Larson SR  et al. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate 73:932-40 (2013). PubMed: 23334979
  • Cohen-Kfir E  et al. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 152:4514-24 (2011). Mouse . PubMed: 21952235
  • Mendoza-Villanueva D  et al. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFß-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res 13:R106 (2011). PubMed: 22032690
  • Mardaryev AN  et al. Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle. FASEB J 24:3869-81 (2010). WB ; Mouse . PubMed: 20522784

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up